Mind the Byte wins 2018 Biosuccess Award Blog Post

CataloniaBio & HealthTech awarded the 2018 Biosuccess Award recognising the most important business milestones in biomedicine and health in Catalonia to Anaconda Biomed and Mind the Byte. The ceremony took place during the CataloniaBio & HealthTech Gala Dinner at the Museu Marítim of Barcelona, featuring president of CataloniaBio & HealthTech, Jaume Amat; CEO of ACCIÓ, Joan Romero; director general for Research and Innovation in Health, Albert Barberà; and over 200 entrepreneurs, executives and investors from the sector.

 

Jaume Amat, CEO of Specipig, new president of CataloniaBio & HealthTech Blog Post

CataloniaBio & HealthTech has chosen its first president and board of directors today, after the merger of the CataloniaBio association of companies and the HealthTech Cluster last December, at an extraordinary members’ assembly. The new entity, located at the Barcelona Science Park, represents more than 170 companies, as well as collaborating stakeholders such as hospitals, research centres and universities that are leaders in R&D in biomedicine.

 

Minoryx starts a phase II/III clinical study of MIN-102 for the treatment of adrenomyeloneuropathy Blog Post

Minoryx Therapeutics –a company specialized in the development of new drugs for orphan diseases, located at the Barcelona Science Park and the TecnoCampus Mataró– announces the start of its pivotal phase II/III clinical trial of MIN-102 for the treatment of adrenomyeloneuropathy (AMN), the most frequent phenotype of X-linked adrenoleukodystrophy (X-ALD). The trial enrolls adult male patients affected by AMN, the most frequent phenotype of X-linked adrenoleukodystrophy (X-ALD).

 

The PCB receives the secondary award for best practice in science and technology parks of APTE Blog Post

Ignasi Belda, CEO of the Barcelona Science Park (PCB), has received this morning the secondary prize of the ‘Award for best practice in science and technology parks of Apte’ in the category of parks with an age of more than 10 years. The award ceremony has been delivered within the framework of the XV International Conference of the Association of Science and Technology Parks of Spain (APTE), which is being held today at the Gipuzkoa Science and Technology Park under the name “Beyond 2020: disruptive technologies“.

 

AVX pharma announces initiation of a Phase 2 Clinical Trial of AVX-012 Ophthalmic Solution in Dry Eye Syndrome Blog Post

Avizorex Pharma (AVX Pharma), a clinical stage biopharmaceutical company with offices at Barcelona Science Park and focused on the development of novel therapies for Dry Eye Syndrome, today announced the initiation of a Phase 2 clinical trial, evaluating the safety and efficacy of AVX-012 Ophthalmic Solution in patients with mild-to-moderate Dry Eye Syndrome, based on the concept of modulating corneal nerve activity to stimulate basal lacrimation.

 

Research in Society 2017-2018 programme kicks off Blog Post

Today, Monday 10 July, the Barcelona Science Park (Parc Científic de Barcelona, PCB) has kicked off its 17th Research in Society programme with the opening of the pre-registration period for the experimental workshops “Discover research!” and “Do research!”. This year, for the first time, places will be allocated to applicant schools in a draw using the list of reservation numbers.

 

SOM Biotech announces a worldwide license with Corino Therapeutics for its SOM0226 compound against amyloidosis Blog Post

SOM Biotech, a leading clinical-stage biopharmaceutical company specialized in drug repurposing to treat rare diseases with a focus on CNS diseases today announces an exclusive worldwide license agreement with U.S. Corino Therapeutics for the clinical development and commercialization of SOM0226, a drug for the treatment of Transthyretin Amyloidosis (ATTR). License was executed after very promising results of the therapeutic agent discovered by SOM –based at the Barcelona Science Park– in a Phase 2a study.

 

Baula has been seclected to become part of the FuTUR Impact program of Ship2B Blog Post

Clean & Health & Eco Baula has been one of the two companies selected to become part of the  FuTUR Impact program, the investment and acceleration platform for high social impact startups in the sector of tourism of the Ship2B Foundation. The company, based at the Barcelona Science Park, has developed an innovative and patented formula worldwide to manufacture and distribute any cleaning product, in the form of individual tablets and easy dissolution, 100% sustainable and responsible to the environment.